Cargando…
A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix
OBJECTIVE: Although advances have been made in the clinical and therapeutic management of women with cervical cancer, the best treatment for patients with metastatic or recurrent cervical cancer is still undefined. Apatinib, a novel inhibitor of vascular endothelial growth factor receptor-2 tyrosine...
Autores principales: | Chen, Chao, Qin, Shukui, Li, Zixiong, Luo, Xianwen, Zhang, Yu, Zhang, Jue, Liu, Xiufeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643513/ https://www.ncbi.nlm.nih.gov/pubmed/31410025 http://dx.doi.org/10.2147/OTT.S212536 |
Ejemplares similares
-
A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019) -
Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis
por: Chen, Chao, et al.
Publicado: (2020) -
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018) -
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
por: Cheng, Yuan, et al.
Publicado: (2018) -
Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective
por: Zheng, Xia, et al.
Publicado: (2021)